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Parenteral nutrition (PN) is life saving for many preterm
infants and other neonates with severe illness, but pro-
longed use of PN can lead to intrahepatic cholestasis,
referred to as parenteral nutrition–associated cholestasis
(PNAC). It is defined as direct bilirubin greater than
2.0 mg/dL persistent for at least 2 consecutive tests dur-
ingthe administration of PN, not associated with other
known causes of cholestasis [1-3].
With the increasing survival of preterm infants and
neonates requiring intensive care, PNAC has become a
more common clinical challenge. The incidence of
PNAC varywidely depending on the population studied,
with high incidencein populations carrying several risk
factors for PNAC. It increases with duration of PN and
ranges from 10% to 85% in infants [4-8].
A multifactorial aetiology has been proposed for the
development of PNAC. Recognized risk factors for PNAC
include low birth weight, low gestational age, necrotizing
enterocolitis, intestinal malformations, and intestinal sur-
gery. A further risk factor is the occurrence ofsevere infec-
tions, due to the requirement for central line for infusion
of PN, and bacterial overgrowth caused by enteralstarva-
tion and immature immune function [9-13].
However, exposure to PN is demonstratedas the main
factor in the development of PNAC. Intravenous hyper-
alimentationhas been implicated, such as thetotal caloric
overload, the quality of aminoacid solutions, the cumula-
tive amount and the quality of lipid infusion, the presence
of excessivealuminium in the PN solution, and the high
manganese intake with PN [1,14-17].
Ursodeoxycholic acid, cyclic PN, light protection for
PN, tapering the soybean-based lipid emulsion, and anti-
biotics to decontaminate bacterial overgrowth are used
to treat PNAC [18-21].
In recent years, increasing attention has been paid to
the lipid content in PN. It has been found that fish
oil–containing lipid emulsions could be useful in
infants to reverse PNAC for whom enteral feeding is
intolerable. However, no evidence supports the use of
fish oil–containing lipid emulsions to prevent PNAC in
neonates, including preterm infants [22].
Enteral feeding remains the best strategy to reverse
and prevent PNAC, with as little as 10% of caloric
intake showing beneficial effects [5,22].
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